<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33839324</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-0024</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Molecular therapy : the journal of the American Society of Gene Therapy</Title><ISOAbbreviation>Mol Ther</ISOAbbreviation></Journal><ArticleTitle>Gene therapy for ALS: A review.</ArticleTitle><Pagination><StartPage>3345</StartPage><EndPage>3358</EndPage><MedlinePgn>3345-3358</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ymthe.2021.04.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1525-0016(21)00195-7</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) has historically posed unique challenges for gene-therapy-based approaches, due to a paucity of therapeutic targets as well as the difficulty of accessing both the brain and spinal cord. Recent advances in our understanding of disease mechanism and ALS genetics, however, have combined with tremendous strides in CNS targeting, gene delivery, and gene editing and knockdown techniques to open new horizons of therapeutic possibility. Gene therapy clinical trials are currently underway for ALS patients with SOD1 mutations, C9orf72 hexanucleotide repeat expansions, ATXN2 trinucleotide expansions, and FUS mutations, as well as sporadic disease without known genetic cause. In this review, we provide an in-depth exploration of the state of ALS-directed gene therapy, including antisense oligonucleotides, RNA interference, CRISPR, adeno-associated virus (AAV)-mediated trophic support, and antibody-based methods. We discuss how each of these approaches has been implemented across known genetic causes as well as sporadic ALS, reviewing preclinical studies as well as completed and ongoing human clinical trials. We highlight the transformative potential of these evolving technologies as the gene therapy field advances toward a true disease-modifying treatment for this devastating illness.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amado</LastName><ForeName>Defne A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: defne@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davidson</LastName><ForeName>Beverly L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. Electronic address: davidsonbl@email.chop.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 NS009435</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS114106</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD012006</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS111671</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther</MedlineTA><NlmUniqueID>100890581</NlmUniqueID><ISSNLinking>1525-0016</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AAV</Keyword><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">ASO</Keyword><Keyword MajorTopicYN="N">CRISPR</Keyword><Keyword MajorTopicYN="N">RNAi</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">gene delivery</Keyword><Keyword MajorTopicYN="N">gene therapy</Keyword></KeywordList><CoiStatement>Declaration of interests B.L.D. is a founder of Spark Therapeutics and Spirovant Sciences and is on the SAB of Patch Bio, Resilience, Saliogen Therapeutics, Panorama Medicines, Homology Medicines, and Spirovant Sciences.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>11</Day><Hour>20</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33839324</ArticleId><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId><ArticleId IdType="pii">S1525-0016(21)00195-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oskarsson B., Gendron T.F., Staff N.P. Amyotrophic Lateral Sclerosis: An Update for 2018. Mayo Clin. Proc. 2018;93:1617&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R., Konstantinova P. Gene Therapy for Neurodegenerative Diseases: Slowing Down the Ticking Clock. Front. Neurosci. 2020;14:580179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7530328</ArticleId><ArticleId IdType="pubmed">33071748</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.J. Overview of current and emerging therapies for amytrophic lateral sclerosis. Am. J. Manag. Care. 2020;26(9, Suppl):S191&#x2013;S197.</Citation><ArticleIdList><ArticleId IdType="pubmed">32840332</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V., ALS/Riluzole Study Group A controlled trial of riluzole in amyotrophic lateral sclerosis. N.&#xa0;Engl. J. Med. 1994;330:585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellingham M.C. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci. Ther. 2011;17:4&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6493865</ArticleId><ArticleId IdType="pubmed">20236142</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Itoyama Y., Sobue G., Tsuji S., Aoki M., Doyu M., Hamada C., Kondo K., Yoneoka T., Akimot M., et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients Amyotroph. Lateral Scler. Frontotemporal Degener. 2014;15:610&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>The Writing Group on Behalf of the Edaravone (MCI-186) ALS 17 Study Group Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis Amyotroph. Lateral Scler. Frontotemporal Degener. 2017;18(Suppl 1):20&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">28872918</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H., Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study) Amyotroph. Lateral Scler. 2006;7:241&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Baradaran-Heravi Y., Van Broeckhoven C., van der Zee J. Stress granule mediated protein aggregation and underlying gene defects in the FTD-ALS spectrum. Neurobiol. Dis. 2020;134:104639.</Citation><ArticleIdList><ArticleId IdType="pubmed">31626953</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R.A., Rademakers R. The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. Neurogenetics. 2007;8:237&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">17805587</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.K., Diehl J., Mendez M.F., Neuhaus J., Shapira J.S., Forman M., Chute D.J., Roberson E.D., Pace-Savitsky C., Neumann M., et al. Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch. Neurol. 2005;62:925&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956163</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs K.A., Holton J.L., Rossor M.N., Godbolt A.K., Ozawa T., Strand K., Khan N., Al-Sarraj S., Revesz T. Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathol. Appl. Neurobiol. 2004;30:369&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">15305982</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Shorter J. Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies. Cold Spring Harb. Perspect. Med. 2017;7:a024554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5580514</ArticleId><ArticleId IdType="pubmed">27920024</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum B.D., Chitta R.K., High A.A., Taylor J.P. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J.&#xa0;Proteome Res. 2010;9:1104&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897173</ArticleId><ArticleId IdType="pubmed">20020773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S.C., Polymenidou M., Cleveland D.W. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton C.F., Cenik C., Kucukural A., Dammer E.B., Cenik B., Han Y., Dewey C.M., Roth F.P., Herz J., Peng J., et al. Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. J.&#xa0;Biol. Chem. 2011;286:1204&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020728</ArticleId><ArticleId IdType="pubmed">21051541</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada S.J., Skibinski G., Korb E., Rao E.J., Wu J.Y., Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J.&#xa0;Neurosci. 2010;30:639&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821110</ArticleId><ArticleId IdType="pubmed">20071528</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu E.Y., Cali C.P., Lee E.B. RNA metabolism in neurodegenerative disease. Dis. Model. Mech. 2017;10:509&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451173</ArticleId><ArticleId IdType="pubmed">28468937</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanden Broeck L., Callaerts P., Dermaut B. TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis? Trends Mol. Med. 2014;20:66&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">24355761</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z., L&#xf3;pez-Erauskin J., Baughn M.W., Zhang O., Drenner K., Sun Y., Freyermuth F., McMahon M.A., Beccari M.S., Artates J.W., et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci. 2019;22:180&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella R., Capitini C., Fani G., Dobson C.M., Cecchi C., Chiti F. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies. J.&#xa0;Biol. Chem. 2016;291:19437&#x2013;19448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016682</ArticleId><ArticleId IdType="pubmed">27445339</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S., Bogaert E., Van Damme P., Van Den Bosch L. Inside out: the role of nucleocytoplasmic transport in ALS and FTLD. Acta Neuropathol. 2016;132:159&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947127</ArticleId><ArticleId IdType="pubmed">27271576</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.-J., Xu Y.F., Cook C., Gendron T.F., Roettges P., Link C.D., Lin W.L., Tong J., Castanedes-Casey M., Ash P., et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc. Natl. Acad. Sci. USA. 2009;106:7607&#x2013;7612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L., Bilgutay A., Zhang Y.J., Vanderweyde T., Citro A., Mehta T., Zaarur N., McKee A., Bowser R., Sherman M., et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS ONE. 2010;5:e13250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952586</ArticleId><ArticleId IdType="pubmed">20948999</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.R., King O.D., Shorter J., Gitler A.D. Stress granules as crucibles of ALS pathogenesis. J.&#xa0;Cell Biol. 2013;201:361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., Daigle J.G., Cunningham K.M., Coyne A.N., Ruan K., Grima J.C., Bowen K.E., Wadhwa H., Yang P., Rigo F., et al. Stress Granule Assembly Disrupts Nucleocytoplasmic Transport. Cell. 2018;173:958&#x2013;971.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R., Chi&#xf2; A., Traynor B.J. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17:94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Rothstein J.D. Rodent Models of Amyotrophic Lateral Sclerosis. Curr. Protoc. Pharmacol. 2015;69:5.67.1&#x2013;5.67.21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce P.I., Fratta P., Fisher E.M.C., Acevedo-Arozena A. SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm. Genome. 2011;22:420&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">21706386</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H., Brooks B.R., Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13:1127&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316019</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D. Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann. Neurol. 2003;53:423&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">12666108</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford N.J., Zhang Y.J., Baker M., Gass J.M., Finch N.A., Xu Y.F., Stewart H., Kelley B.J., Kuntz K., Crook R.J., et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008;4:e1000193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527686</ArticleId><ArticleId IdType="pubmed">18802454</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens J., Wils H., Kleinberger G., Joris G., Cuijt I., Ceuterick-de Groote C., Van Broeckhoven C., Kumar-Singh S. Overexpression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. Mol. Neurobiol. 2013;48:22&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3718993</ArticleId><ArticleId IdType="pubmed">23475610</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H., Kleinberger G., Janssens J., Pereson S., Joris G., Cuijt I., Smits V., Ceuterick-de Groote C., Van Broeckhoven C., Kumar-Singh S. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2010;107:3858&#x2013;3863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski T.J., Jr., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Rogelj B., Hortob&#xe1;gyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden A.C., Kim H.J., Hart M.P., Chen-Plotkin A.S., Johnson B.S., Fang X., Armakola M., Geser F., Greene R., Lu M.M., et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Sim&#xf3;n-S&#xe1;nchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. ITALSGEN Consortium A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E., Renton A.E., Mok K., Dopper E.G., Waite A., Rollinson S., Chi&#xf2; A., Restagno G., Nicolaou N., Simon-Sanchez J., et al. Chromosome 9-ALS/FTD Consortium. French research network on FTLD/FTLD/ALS. ITALSGEN Consortium Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Pattamatta A., Zu T., Reid T., Bardhi O., Borchelt D.R., Yachnis A.T., Ranum L.P. C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD. Neuron. 2016;90:521&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra R., Lee C.W. Mouse Models of C9orf72 Hexanucleotide Repeat Expansion in Amyotrophic Lateral Sclerosis/ Frontotemporal Dementia. Front. Cell. Neurosci. 2017;11:196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5498553</ArticleId><ArticleId IdType="pubmed">28729824</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Chi&#xf2; A., Traynor B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014;17:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappella M., Ciotti C., Cohen-Tannoudji M., Biferi M.G. Gene Therapy for ALS-A Perspective. Int. J. Mol. Sci. 2019;20:4388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6771059</ArticleId><ArticleId IdType="pubmed">31500113</ArticleId></ArticleIdList></Reference><Reference><Citation>Murlidharan G., Samulski R.J., Asokan A. Biology of adeno-associated viral vectors in the central nervous system. Front. Mol. Neurosci. 2014;7:76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4168676</ArticleId><ArticleId IdType="pubmed">25285067</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosolini A.P., Sleigh J.N. Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci. 2017;10:405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5725447</ArticleId><ArticleId IdType="pubmed">29270111</ArticleId></ArticleIdList></Reference><Reference><Citation>Colella P., Ronzitti G., Mingozzi F. Emerging Issues in AAV-Mediated In&#xa0;Vivo Gene Therapy. Mol. Ther. Methods Clin. Dev. 2017;8:87&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5758940</ArticleId><ArticleId IdType="pubmed">29326962</ArticleId></ArticleIdList></Reference><Reference><Citation>Duque S., Joussemet B., Riviere C., Marais T., Dubreil L., Douar A.M., Fyfe J., Moullier P., Colle M.A., Barkats M. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 2009;17:1187&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2835208</ArticleId><ArticleId IdType="pubmed">19367261</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanguy Y., Biferi M.G., Besse A., Astord S., Cohen-Tannoudji M., Marais T., Barkats M. Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice. Front. Mol. Neurosci. 2015;8:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516891</ArticleId><ArticleId IdType="pubmed">26283910</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust K.D., Wang X., McGovern V.L., Braun L., Bevan A.K., Haidet A.M., Le T.T., Morales P.R., Rich M.M., Burghes A.H., Kaspar B.K. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 2010;28:271&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889698</ArticleId><ArticleId IdType="pubmed">20190738</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez E., Marais T., Chatauret N., Benkhelifa-Ziyyat S., Duque S., Ravassard P., Carcenac R., Astord S., Pereira de Moura A., Voit T., Barkats M. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum. Mol. Genet. 2011;20:681&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pubmed">21118896</ArticleId></ArticleIdList></Reference><Reference><Citation>Valori C.F., Ning K., Wyles M., Mead R.J., Grierson A.J., Shaw P.J., Azzouz M. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci. Transl. Med. 2010;2:35ra42.</Citation><ArticleIdList><ArticleId IdType="pubmed">20538619</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell J.R., Al-Zaidy S., Shell R., Arnold W.D., Rodino-Klapac L.R., Prior T.W., Lowes L., Alfano L., Berry K., Church K., et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N.&#xa0;Engl. J. Med. 2017;377:1713&#x2013;1722.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Deverman B.E., Pravdo P.L., Simpson B.P., Kumar S.R., Chan K.Y., Banerjee A., Wu W.L., Yang B., Huber N., Pasca S.P., Gradinaru V. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 2016;34:204&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5088052</ArticleId><ArticleId IdType="pubmed">26829320</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K.Y., Jang M.J., Yoo B.B., Greenbaum A., Ravi N., Wu W.L., S&#xe1;nchez-Guardado L., Lois C., Mazmanian S.K., Deverman B.E., Gradinaru V. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 2017;20:1172&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5529245</ArticleId><ArticleId IdType="pubmed">28671695</ArticleId></ArticleIdList></Reference><Reference><Citation>Challis R.C., Ravindra Kumar S., Chan K.Y., Challis C., Beadle K., Jang M.J., Kim H.M., Rajendran P.S., Tompkins J.D., Shivkumar K., et al. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nat. Protoc. 2019;14:379&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">30626963</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzouz M. Gene Therapy for ALS: progress and prospects. Biochim. Biophys. Acta. 2006;1762:1122&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">16806843</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury S.R., Hudry E., Maguire C.A., Sena-Esteves M., Breakefield X.O., Grandi P. Viral vectors for therapy of neurologic diseases. Neuropharmacology. 2017;120:63&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5929167</ArticleId><ArticleId IdType="pubmed">26905292</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M., Svendsen C.N. Ex&#xa0;Vivo Gene Therapy Using Human Mesenchymal Stem Cells to Deliver Growth Factors in the Skeletal Muscle of a Familial ALS Rat Model. Methods Mol. Biol. 2016;1382:325&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">26611598</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly C.V., Miller T.M. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2018;31:648&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7291817</ArticleId><ArticleId IdType="pubmed">30028737</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoch K.M., Miller T.M. Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases. Neuron. 2017;94:1056&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5821515</ArticleId><ArticleId IdType="pubmed">28641106</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett C.F., Swayze E.E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 2010;50:259&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">20055705</ArticleId></ArticleIdList></Reference><Reference><Citation>Passini M.A., Bu J., Richards A.M., Kinnecom C., Sardi S.P., Stanek L.M., Hua Y., Rigo F., Matson J., Hung G., et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 2011;3:72ra18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140425</ArticleId><ArticleId IdType="pubmed">21368223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiriboga C.A., Swoboda K.J., Darras B.T., Iannaccone S.T., Montes J., De Vivo D.C., Norris D.A., Bennett C.F., Bishop K.M. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86:890&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4782111</ArticleId><ArticleId IdType="pubmed">26865511</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel R.S., Chiriboga C.A., Vajsar J., Day J.W., Montes J., De Vivo D.C., Yamashita M., Rigo F., Hung G., Schneider E., et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388:3017&#x2013;3026.</Citation><ArticleIdList><ArticleId IdType="pubmed">27939059</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel R.S., Mercuri E., Darras B.T., Connolly A.M., Kuntz N.L., Kirschner J., Chiriboga C.A., Saito K., Servais L., Tizzano E., et al. ENDEAR Study Group Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N.&#xa0;Engl. J. Med. 2017;377:1723&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekhtiari Bidhendi E., Bergh J., Zetterstr&#xf6;m P., Forsberg K., Pakkenberg B., Andersen P.M., Marklund S.L., Br&#xe4;nnstr&#xf6;m T. Mutant superoxide dismutase aggregates from human spinal cord transmit amyotrophic lateral sclerosis. Acta Neuropathol. 2018;136:939&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280858</ArticleId><ArticleId IdType="pubmed">30284034</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripps M.E., Huntley G.W., Hof P.R., Morrison J.H., Gordon J.W. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 1995;92:689&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42685</ArticleId><ArticleId IdType="pubmed">7846037</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M., Aoki M., Miyoshi I., Kato M., Pasinelli P., Kasai N., Brown R.H., Jr., Itoyama Y. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J.&#xa0;Neurosci. 2001;21:9246&#x2013;9254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763929</ArticleId><ArticleId IdType="pubmed">11717358</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.A., Miller T.M., Yamanaka K., Monia B.P., Condon T.P., Hung G., Lobsiger C.S., Ward C.M., McAlonis-Downes M., Wei H., et al. Antisense oligonucleotide therapy for neurodegenerative disease. J.&#xa0;Clin. Invest. 2006;116:2290&#x2013;2296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Pestronk A., David W., Rothstein J., Simpson E., Appel S.H., Andres P.L., Mahoney K., Allred P., Alexander K., et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C., Genge A., Glass J., Ladha S., Ludolph A.L., et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N.&#xa0;Engl. J. Med. 2020;383:109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Biferi M.G., Cohen-Tannoudji M., Cappelletto A., Giroux B., Roda M., Astord S., Marais T., Bos C., Voit T., Ferry A., Barkats M. A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model. Mol. Ther. 2017;25:2038&#x2013;2052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5589057</ArticleId><ArticleId IdType="pubmed">28663100</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly C.J., Zhang P.W., Pham J.T., Haeusler A.R., Mistry N.A., Vidensky S., Daley E.L., Poth E.M., Hoover B., Fines D.M., et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R., Isaacs A.M. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat. Rev. Neurol. 2018;14:544&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Baughn M., Rigo F., Sun S., Liu P., Li H.R., Jiang J., Watt A.T., Chun S., Katz M., et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. USA. 2013;110:E4530&#x2013;E4539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D., O&#x2019;Rourke J.G., Meera P., Muhammad A.K., Grant S., Simpkinson M., Bell S., Carmona S., Ornelas L., Sahabian A., et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 2013;5:208ra149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J., Zhu Q., Gendron T.F., Saberi S., McAlonis-Downes M., Seelman A., Stauffer J.E., Jafar-Nejad P., Drenner K., Schulte D., et al. Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron. 2016;90:535&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbert G., Saudou F., Yvert G., Devys D., Trottier Y., Garnier J.M., Weber C., Mandel J.L., Cancel G., Abbas N., et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat. Genet. 1996;14:285&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896557</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulst S.M., Nechiporuk A., Nechiporuk T., Gispert S., Chen X.N., Lopes-Cendes I., Pearlman S., Starkman S., Orozco-Diaz G., Lunkes A., et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat. Genet. 1996;14:269&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896555</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanpei K., Takano H., Igarashi S., Sato T., Oyake M., Sasaki H., Wakisaka A., Tashiro K., Ishida Y., Ikeuchi T., et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat. Genet. 1996;14:277&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896556</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez M., McClain M.E., Martinez R.A., Snow K., Lipe H., Ravits J., Bird T.D., La Spada A.R. Late-onset SCA2: 33 CAG repeats are sufficient to cause disease. Neurology. 2000;55:569&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">10953195</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z., Zhu Y., Chen-Plotkin A.S., Clay-Falcone D., McCluskey L., Elman L., Kalb R.G., Trojanowski J.Q., Lee V.M., Van Deerlin V.M., et al. PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. PLoS ONE. 2011;6:e17951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3066214</ArticleId><ArticleId IdType="pubmed">21479228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T., Li Y.R., Ingre C., Weber M., Grehl T., Gredal O., de Carvalho M., Meyer T., Tysnes O.B., Auburger G., et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum. Mol. Genet. 2011;20:1697&#x2013;1700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071667</ArticleId><ArticleId IdType="pubmed">21292779</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., Veldink J.H., van Blitterswijk M., Corveleyn A., van Vught P.W., Thijs V., Dubois B., Matthijs G., van den Berg L.H., Robberecht W. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology. 2011;76:2066&#x2013;2072.</Citation><ArticleIdList><ArticleId IdType="pubmed">21562247</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonhoff U., Ralser M., Welzel F., Piccini I., Balzereit D., Yaspo M.L., Lehrach H., Krobitsch S. Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol. Biol. Cell. 2007;18:1385&#x2013;1396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838996</ArticleId><ArticleId IdType="pubmed">17392519</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart M.P., Gitler A.D. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. J.&#xa0;Neurosci. 2012;32:9133&#x2013;9142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3418890</ArticleId><ArticleId IdType="pubmed">22764223</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Heuvel D.M.A., Harschnitz O., van den Berg L.H., Pasterkamp R.J. Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis? Trends Mol. Med. 2014;20:25&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">24140266</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker L.A., Huang B., Bieri G., Ma R., Knowles D.A., Jafar-Nejad P., Messing J., Kim H.J., Soriano A., Auburger G., et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte A., Lattante S., Zollino M., Marangi G., Luigetti M., Del Grande A., Servidei S., Trombetta F., Sabatelli M. P525L FUS mutation is consistently associated with a severe form of juvenile amyotrophic lateral sclerosis. Neuromuscul. Disord. 2012;22:73&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">21907581</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappella M., Pradat P.-F., Querin G., Biferi M.G. Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy. J.&#xa0;Neuromuscul. Dis. 2021;8:25&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7902976</ArticleId><ArticleId IdType="pubmed">33074186</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold C. Tailored treatment for ALS poised to move ahead. Nat. Med. 2019 doi: 10.1038/d41591-019-00013-w. Published online May 30, 2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41591-019-00013-w</ArticleId><ArticleId IdType="pubmed">32467611</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueiredo M.  2020. Collaboration Funds Experimental Therapy for Rare FUS-ALS.https://alsnewstoday.com/news-posts/2020/03/16/jacifusen-collaboration-funds-experimental-therapy-for-patients-with-rare-fus-als/</Citation></Reference><Reference><Citation>ALS Association.   2021. The ALS Association and Project ALS to Fund Columbia University Drug Trial for Patients with Rare Genetic Forms of ALS.http://web.alsa.org/site/PageNavigator/blog_021420.html</Citation></Reference><Reference><Citation>Borel F., Kay M.A., Mueller C. Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol. Ther. 2014;22:692&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3982504</ArticleId><ArticleId IdType="pubmed">24352214</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudreau R.L., Martins I., Davidson B.L. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in&#xa0;vitro and in&#xa0;vivo. Mol. Ther. 2009;17:169&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834985</ArticleId><ArticleId IdType="pubmed">19002161</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride J.L., Boudreau R.L., Harper S.Q., Staber P.D., Monteys A.M., Martins I., Gilmore B.L., Burstein H., Peluso R.W., Polisky B., et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. USA. 2008;105:5868&#x2013;5873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2311380</ArticleId><ArticleId IdType="pubmed">18398004</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudreau R.L., Spengler R.M., Hylock R.H., Kusenda B.J., Davis H.A., Eichmann D.A., Davidson B.L. siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse. Nucleic Acids Res. 2013;41:e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3592398</ArticleId><ArticleId IdType="pubmed">22941647</ArticleId></ArticleIdList></Reference><Reference><Citation>Evers M.M., Miniarikova J., Juhas S., Vall&#xe8;s A., Bohuslavova B., Juhasova J., Skalnikova H.K., Vodicka P., Valekova I., Brouwers C., et al. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington&#x2019;s Disease Minipig Model. Mol. Ther. 2018;26:2163&#x2013;2177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6127509</ArticleId><ArticleId IdType="pubmed">30007561</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6286148</ArticleId><ArticleId IdType="pubmed">22745249</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795411</ArticleId><ArticleId IdType="pubmed">23287718</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun Y., Ha Y. CRISPR/Cas9-Mediated Gene Correction to Understand ALS. Int. J. Mol. Sci. 2020;21:3801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7312396</ArticleId><ArticleId IdType="pubmed">32471232</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzalone A.V., Koblan L.W., Liu D.R. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 2020;38:824&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">32572269</ArticleId></ArticleIdList></Reference><Reference><Citation>Burmistrz M., Krakowski K., Krawczyk-Balska A. RNA-Targeting CRISPR-Cas Systems and Their Applications. Int. J. Mol. Sci. 2020;21:1122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7036953</ArticleId><ArticleId IdType="pubmed">32046217</ArticleId></ArticleIdList></Reference><Reference><Citation>Doudna J.A. The promise and challenge of therapeutic genome editing. Nature. 2020;578:229&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8992613</ArticleId><ArticleId IdType="pubmed">32051598</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Zhang F., Gao G. CRISPR-Based Therapeutic Genome Editing: Strategies and In&#xa0;Vivo Delivery by AAV Vectors. Cell. 2020;181:136&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7236621</ArticleId><ArticleId IdType="pubmed">32243786</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi L.S., Larson M.H., Gilbert L.A., Doudna J.A., Weissman J.S., Arkin A.P., Lim W.A. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152:1173&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664290</ArticleId><ArticleId IdType="pubmed">23452860</ArticleId></ArticleIdList></Reference><Reference><Citation>Abudayyeh O.O., Gootenberg J.S., Konermann S., Joung J., Slaymaker I.M., Cox D.B., Shmakov S., Makarova K.S., Semenova E., Minakhin L., et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science. 2016;353:aaf5573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127784</ArticleId><ArticleId IdType="pubmed">27256883</ArticleId></ArticleIdList></Reference><Reference><Citation>Abudayyeh O.O., Gootenberg J.S., Essletzbichler P., Han S., Joung J., Belanto J.J., Verdine V., Cox D.B.T., Kellner M.J., Regev A., et al. RNA targeting with CRISPR-Cas13. Nature. 2017;550:280&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5706658</ArticleId><ArticleId IdType="pubmed">28976959</ArticleId></ArticleIdList></Reference><Reference><Citation>Konermann S., Lotfy P., Brideau N.J., Oki J., Shokhirev M.N., Hsu P.D. Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors. Cell. 2018;173:665&#x2013;676.e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5910255</ArticleId><ArticleId IdType="pubmed">29551272</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzalone A.V., Randolph P.B., Davis J.R., Sousa A.A., Koblan L.W., Levy J.M., Chen P.J., Wilson C., Newby G.A., Raguram A., Liu D.R. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6907074</ArticleId><ArticleId IdType="pubmed">31634902</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust K.D., Salazar D.L., Likhite S., Ferraiuolo L., Ditsworth D., Ilieva H., Meyer K., Schmelzer L., Braun L., Cleveland D.W., Kaspar B.K. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol. Ther. 2013;21:2148&#x2013;2159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3863799</ArticleId><ArticleId IdType="pubmed">24008656</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust K.D., Nurre E., Montgomery C.L., Hernandez A., Chan C.M., Kaspar B.K. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 2009;27:59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895694</ArticleId><ArticleId IdType="pubmed">19098898</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen G.M., Gowing G., Latter J., Chen M., Vit J.P., Staggenborg K., Avalos P., Alkaslasi M., Ferraiuolo L., Likhite S., et al. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J.&#xa0;Neurosci. 2014;34:15587&#x2013;15600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4298650</ArticleId><ArticleId IdType="pubmed">25411487</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L., Todeasa S.H., Cabrera G.T., Salameh J.S., ElMallah M.K., Mueller C., Brown R.H., Jr., Sena-Esteves M. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann. Neurol. 2016;79:687&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5374859</ArticleId><ArticleId IdType="pubmed">26891182</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F., Gernoux G., Cardozo B., Metterville J.P., Toro Cabrera G.C., Song L., Su Q., Gao G.P., Elmallah M.K., Brown R.H., Jr., Mueller C. Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates. Hum. Gene Ther. 2016;27:19&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4741242</ArticleId><ArticleId IdType="pubmed">26710998</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F., Gernoux G., Sun H., Stock R., Blackwood M., Brown R.H., Jr., Mueller C. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci. Transl. Med. 2018;10:eaau6414.</Citation><ArticleIdList><ArticleId IdType="pubmed">30381409</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C., Berry J.D., McKenna-Yasek D.M., Gernoux G., Owegi M.A., Pothier L.M., Douthwright C.L., Gelevski D., Luppino S.D., Blackwood M., et al. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N.&#xa0;Engl. J. Med. 2020;383:151&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinderer C., Katz N., Buza E.L., Dyer C., Goode T., Bell P., Richman L.K., Wilson J.M. Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum. Gene Ther. 2018;29:285&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5865262</ArticleId><ArticleId IdType="pubmed">29378426</ArticleId></ArticleIdList></Reference><Reference><Citation>Hordeaux J., Buza E.L., Dyer C., Goode T., Mitchell T.W., Richman L., Denton N., Hinderer C., Katz N., Schmid R., et al. Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology. Hum. Gene Ther. 2020;31:808&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">32845779</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeler A.M., Zieger M., Semple C., Pucci L., Veinbachs A., Brown R.H., Jr., Mueller C., ElMallah M.K. Intralingual and Intrapleural AAV Gene Therapy Prolongs Survival in a SOD1 ALS Mouse Model. Mol. Ther. Methods Clin. Dev. 2019;17:246&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6962641</ArticleId><ArticleId IdType="pubmed">31970202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hordeaux J., Buza E.L., Jeffrey B., Song C., Jahan T., Yuan Y., Zhu Y., Bell P., Li M., Chichester J.A., et al. MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates. Sci. Transl. Med. 2020;12:eaba9188.</Citation><ArticleIdList><ArticleId IdType="pubmed">33177182</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo-Hernandez M., Tadokoro T., Navarro M.R., Platoshyn O., Kobayashi Y., Marsala S., Miyanohara A., Jushas S., Juhasova J., Skalnikova H., et al. Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS. Nat. Med. 2020;26:118&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8171115</ArticleId><ArticleId IdType="pubmed">31873312</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T., Ojala D.S., Ekman F.K., Byrne L.C., Limsirichai P., Schaffer D.V. In&#xa0;vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci. Adv. 2017;3:eaar3952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5738228</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan W., Guo M., Yi L., Liu Y., Li Z., Ma Y., Zhang G., Liu Y., Bu H., Song X., et al. The deletion of mutant SOD1 via CRISPR/Cas9/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model. Gene Ther. 2020;27:157&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">31819203</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim C.K.W., Gapinske M., Brooks A.K., Woods W.S., Powell J.E., Zeballos C M.A., Winter J., Perez-Pinera P., Gaj T. Treatment of a Mouse Model of ALS by In&#xa0;Vivo Base Editing. Mol. Ther. 2020;28:1177&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132599</ArticleId><ArticleId IdType="pubmed">31991108</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S., Meister G. SsiRNA design principles and off-target effects. Methods Mol. Biol. 2013;986:59&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">23436405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J., Liu J., Li L., Gagnon K.T., Corey D.R. Engineering Duplex RNAs for Challenging Targets: Recognition of GGGGCC/CCCCGG Repeats at the ALS/FTD C9orf72 Locus. Chem. Biol. 2015;22:1505&#x2013;1511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4659491</ArticleId><ArticleId IdType="pubmed">26584779</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J., Rigo F., Prakash T.P., Corey D.R. Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs. Nucleic Acid Ther. 2017;27:87&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5372765</ArticleId><ArticleId IdType="pubmed">28005462</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R., Liefhebber J.M., Miniarikova J., van der Zon T., Snapper J., Kolder I., Petry H., van Deventer S.J., Evers M.M., Konstantinova P. Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. Mol. Ther. Nucleic Acids. 2019;14:593&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6378669</ArticleId><ArticleId IdType="pubmed">30776581</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R., Liefhebber J.M., Garc&#xed;a-Osta A., Miniarikova J., Cuadrado-Tejedor M., Espelosin M., Ursua S., Petry H., van Deventer S.J., Evers M.M., Konstantinova P. Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. Mol. Ther. Nucleic Acids. 2019;16:26&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6393708</ArticleId><ArticleId IdType="pubmed">30825670</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan G., Zhang Y., Gu Y., Kankel M.W., Gao F.B., Almeida S. CRISPR deletion of the C9ORF72 promoter in ALS/FTD patient motor neurons abolishes production of dipeptide repeat proteins and rescues neurodegeneration. Acta Neuropathol. 2020;140:81&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300081</ArticleId><ArticleId IdType="pubmed">32266467</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R., Yang D., Pribadi M., Kim T.S., Krishnan G., Choi S.Y., Lee S., Coppola G., Gao F.B. Partial inhibition of the overactivated Ku80-dependent DNA repair pathway rescues neurodegeneration in C9ORF72-ALS/FTD. Proc. Natl. Acad. Sci. USA. 2019;116:9628&#x2013;9633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6511021</ArticleId><ArticleId IdType="pubmed">31019093</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles D.R., Meera P., Schneider M., Paul S., Dansithong W., Figueroa K.P., et al. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature. 2017;544:362&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6625650</ArticleId><ArticleId IdType="pubmed">28405024</ArticleId></ArticleIdList></Reference><Reference><Citation>Keiser M.S., Boudreau R.L., Davidson B.L. Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy. Mol. Ther. 2014;22:588&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944323</ArticleId><ArticleId IdType="pubmed">24419082</ArticleId></ArticleIdList></Reference><Reference><Citation>Keiser M.S., Monteys A.M., Corbau R., Gonzalez-Alegre P., Davidson B.L. RNAi prevents and reverses phenotypes induced by mutant human ataxin-1. Ann. Neurol. 2016;80:754&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5115960</ArticleId><ArticleId IdType="pubmed">27686464</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xf3;brega C., Nascimento-Ferreira I., Onofre I., Albuquerque D., Hirai H., D&#xe9;glon N., de Almeida L.P. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice. PLoS ONE. 2013;8:e52396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551966</ArticleId><ArticleId IdType="pubmed">23349684</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xf3;brega C., Nascimento-Ferreira I., Onofre I., Albuquerque D., D&#xe9;glon N., de Almeida L.P. RNA interference mitigates motor and neuropathological deficits in a cerebellar mouse model of Machado-Joseph disease. PLoS ONE. 2014;9:e100086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4140724</ArticleId><ArticleId IdType="pubmed">25144231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran P.S., Boudreau R.L., Schaefer K.A., La Spada A.R., Davidson B.L. Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7. Mol. Ther. 2014;22:1635&#x2013;1642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4435484</ArticleId><ArticleId IdType="pubmed">24930601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang S., Xie Y., Xiong Z., Yang Y., Xian Y., Ou Z., Song B., Chen Y., Xie Y., Li H., Sun X. CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells. Stem Cells Dev. 2018;27:756&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">29661116</ArticleId></ArticleIdList></Reference><Reference><Citation>Buijsen R.A.M., Toonen L.J.A., Gardiner S.L., van Roon-Mom W.M.C. Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias. Neurotherapeutics. 2019;16:263&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554265</ArticleId><ArticleId IdType="pubmed">30607747</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D., Mansfield C., Moussy A., Hermine O. ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? Front. Aging Neurosci. 2017;9:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartus R.T., Johnson E.M., Jr. Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: Where have we been and what have we learned? Neurobiol. Dis. 2017;97:156&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">27063798</ArticleId></ArticleIdList></Reference><Reference><Citation>Allodi I., Comley L., Nichterwitz S., Nizzardo M., Simone C., Benitez J.A., Cao M., Corti S., Hedlund E. Differential neuronal vulnerability identifies IGF-2 as a protective factor in ALS. Sci. Rep. 2016;6:25960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867585</ArticleId><ArticleId IdType="pubmed">27180807</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H., Hu H., Duan W., Liu Y., Tan G., Li Z., Liu Y., Deng B., Song X., Wang W., et al. Intramuscular Delivery of scAAV9-hIGF1 Prolongs Survival in the hSOD1 G93A ALS Mouse Model via Upregulation of D-Amino Acid Oxidase. Mol. Neurobiol. 2018;55:682&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">27995572</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Wen D., Duan W., Yin J., Cui C., Wang Y., Li Z., Liu Y., Li C. Systemic administration of scAAV9-IGF1 extends survival in SOD1G93A ALS mice via inhibiting p38 MAPK and the JNK-mediated apoptosis pathway. Brain Res. Bull. 2018;139:203&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">29499331</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge J.C., Treleaven C.M., Fidler J.A., Hester M., Haidet A., Handy C., Rao M., Eagle A., Matthews J.C., Taksir T.V., et al. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol. Ther. 2010;18:2075&#x2013;2084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997594</ArticleId><ArticleId IdType="pubmed">20859261</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Duan W., Cui C., Liu Y., Li C., Liu Y. AAV9-IGF1 protects TDP-25 cells from apoptosis and oxidative stress partly via up-regulating the expression of VEGF in&#xa0;vitro. Neurosci. Lett. 2017;640:123&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">28108397</ArticleId></ArticleIdList></Reference><Reference><Citation>Keifer O.P., Jr., O&#x2019;Connor D.M., Boulis N.M. Gene and protein therapies utilizing VEGF for ALS. Pharmacol. Ther. 2014;141:261&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4659499</ArticleId><ArticleId IdType="pubmed">24177067</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Duan W., Wang W., Wen D., Liu Y., Liu Y., Li Z., Hu H., Lin H., Cui C., et al. scAAV9-VEGF prolongs the survival of transgenic ALS mice by promoting activation of M2 microglia and the PI3K/Akt pathway. Brain Res. 2016;1648:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">27392886</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucher T., Colle M.A., Wakeling E., Dubreil L., Fyfe J., Briot-Nivard D., Maquigneau M., Raoul S., Cherel Y., Astord S., et al. scAAV9 intracisternal delivery results in efficient gene transfer to the central nervous system of a feline model of motor neuron disease. Hum. Gene Ther. 2013;24:670&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">23799774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L.-J., Lu Y.Y., Muramatsu S., Ikeguchi K., Fujimoto K., Okada T., Mizukami H., Matsushita T., Hanazono Y., Kume A., et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J.&#xa0;Neurosci. 2002;22:6920&#x2013;6928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757879</ArticleId><ArticleId IdType="pubmed">12177190</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Brakefield D., Pan Y., Hunter D., Myckatyn T.M., Parsadanian A. Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse model of ALS. Exp. Neurol. 2007;203:457&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">17034790</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen G.M., Alkaslasi M., Vit J.P., Lawless G., Godoy M., Gowing G., Shelest O., Svendsen C.N. Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1G93A ALS rat but has adverse side effects. Gene Ther. 2017;24:245&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404206</ArticleId><ArticleId IdType="pubmed">28276446</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A., Pitzer C., Dittgen T., Klugmann M., Dupuis L., Schneider A. CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit. Mol. Ther. 2011;19:284&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034860</ArticleId><ArticleId IdType="pubmed">21139572</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.H., Kim S., Lee N., Lee J., Yu S.S., Kim J.H., Kim S. Intrathecal delivery of recombinant AAV1 encoding hepatocyte growth factor improves motor functions and protects neuromuscular system in the nerve crush and SOD1-G93A transgenic mouse models. Acta Neuropathol. Commun. 2019;7:96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6563368</ArticleId><ArticleId IdType="pubmed">31189468</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.H., Lee N., Kim S., Lee J., Choi W., Yu S.S., Kim J.H., Kim S. Intramuscular delivery of HGF-expressing recombinant AAV improves muscle integrity and alleviates neurological symptoms in the nerve crush and SOD1-G93A transgenic mouse models. Biochem. Biophys. Res. Commun. 2019;517:452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">31376938</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., Mart&#xed;nez-Muriana A., Leiva T., Gregorio D., Ariza L., Morell M., Esteban-P&#xe9;rez J., Garc&#xed;a-Redondo A., Calvo A.C., Atencia-Cibreiro G., et al. Neuregulin-1 promotes functional improvement by enhancing collateral sprouting in SOD1(G93A) ALS mice and after partial muscle denervation. Neurobiol. Dis. 2016;95:168&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">27461051</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyoshi S., Tezuka T., Arimura S., Tomono T., Okada T., Yamanashi Y. DOK7 gene therapy enhances motor activity and life span in ALS model mice. EMBO Mol. Med. 2017;9:880&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494517</ArticleId><ArticleId IdType="pubmed">28490573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Duan W., Wang Y., Wen D., Liu Y., Li Z., Hu H., Cui H., Cui C., Lin H., Li C. Intrathecal Delivery of ssAAV9-DAO Extends Survival in SOD1 G93A ALS Mice. Neurochem. Res. 2017;42:986&#x2013;996.</Citation><ArticleIdList><ArticleId IdType="pubmed">28025800</ArticleId></ArticleIdList></Reference><Reference><Citation>Israelson A., Ditsworth D., Sun S., Song S., Liang J., Hruska-Plochan M., McAlonis-Downes M., Abu-Hamad S., Zoltsman G., Shani T., et al. Macrophage migration inhibitory factor as a chaperone inhibiting accumulation of misfolded SOD1. Neuron. 2015;86:218&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393372</ArticleId><ArticleId IdType="pubmed">25801706</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyton-Jaimes M.F., Kahn J., Israelson A. AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS. Proc. Natl. Acad. Sci. USA. 2019;116:14755&#x2013;14760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6642395</ArticleId><ArticleId IdType="pubmed">31262807</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P., Kriz J., Gravel M., Soucy G., Bareil C., Gravel C., Julien J.P. Adeno-associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis. Mol. Ther. 2014;22:498&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944333</ArticleId><ArticleId IdType="pubmed">24394188</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi S., Thammisetty S.S., Codron P., Rahimian R., Plourde K.V., Soucy G., Bareil C., Phaneuf D., Kriz J., Gravel C., Julien J.P. Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology. J.&#xa0;Clin. Invest. 2019;129:1581&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6436898</ArticleId><ArticleId IdType="pubmed">30667370</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>